China Health Resource, Inc. Announces a Profitable Year Under New Management

Share Article

China Health Resource, Inc. achieves record revenues of over $10 million, earnings per share of US$0.0183

Dahurian Angelica Root

China Health Resource, Inc.(OTCBB: CHRI) announced on April 11, 2011, its financial results for fiscal year ending December 31, 2010. The report reflects 2010’s annual revenue of US$10,282,207, an increase of 134 percent from the previous year.

“We are pleased to announce a great year (2010) for the Company. Our continuous efforts to support the consumer with a better, healthier lifestyle choice, and diligent work in providing only the best quality herbs for the people of China has resulted in an increase of 134 percent compared to year-end 2009,” said Jiayin Wang, CEO.

CHRI’s net income of US$2,785,881 was a result from increased sales, lower SG&A expense, and a foreign currency translation gain between the RMB and USD of US$78,595.

CHRI has mapped out its plans for 2011, placing a strong emphasis on sales and increasing distribution for current and new additions to its line of Traditional Chinese Medicine (“TCM”). The Company plans on leveraging government programs in the agricultural sector, driven by substantial market demand, to increase margins for its line of TCM drugs.

"We ended 2010 with record revenues and robust demand for Sichuan Angelica products across all geographies and channels in China," said Mr Wang. “In 2011, we look forward to continued growth as we ramp our sales and distribution strategies, and expand our product line to new TCM drugs."

Additional information about China Health Resource, Inc. and the annual report can be found by visiting http://ChinaHealthResource.com under “Investor Relations.”

About CHRI
China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the People's Republic of China. DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rebecca Binny-Hallmark
Visit website